Q-omics provides the consensus-scored PRAMEF1 profile across patient tissues and cancer cell-line models. PRAMEF1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRAMEF1 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, PRAMEF1 protein abundance shows 19,336 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where PRAMEF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF1 survival associations across molecular data types. PRAMEF1 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF1 RNA expression–survival associations across cancer types. High PRAMEF1 expression shows unfavorable associations in KIRC, CHOL, HNSC, BLCA and OV, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRAMEF1 RNA expression.
This table summarizes PRAMEF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PRAMEF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAMEF1 shows lower tumor expression in THCA and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher PRAMEF1 RNA expression in tumor versus normal tissue (log2 FC = +0.004, t-test p = .023).
This table shows molecular features associated with PRAMEF1 in patient tissues and cancer cell lines. In patient samples, PRAMEF1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
